Pharma Mar SAU
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, China, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis, a syntheti… Read more
Market Cap & Net Worth: Pharma Mar SAU (PHMMF)
Pharma Mar SAU (PINK:PHMMF) has a market capitalization of $1.51 Billion ($1.51 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #6620 globally and #3686 in its home market, demonstrating a -13.61% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pharma Mar SAU's stock price $88.18 by its total outstanding shares 17088535 (17.09 Million).
Pharma Mar SAU Market Cap History: 2015 to 2025
Pharma Mar SAU's market capitalization history from 2015 to 2025. Data shows growth from $891.92 Million to $1.51 Billion (5.71% CAGR).
Pharma Mar SAU Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pharma Mar SAU's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
7.33x
Pharma Mar SAU's market cap is 7.33 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
49.06x
Pharma Mar SAU's market cap is 49.06 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $891.92 Million | $192.81 Million | $6.59 Million | 4.63x | 135.39x |
| 2016 | $567.32 Million | $180.94 Million | -$24.08 Million | 3.14x | N/A |
| 2017 | $591.98 Million | $179.34 Million | -$26.75 Million | 3.30x | N/A |
| 2018 | $238.77 Million | $162.16 Million | -$5.54 Million | 1.47x | N/A |
| 2019 | $779.45 Million | $85.82 Million | -$9.18 Million | 9.08x | N/A |
| 2020 | $1.44 Billion | $269.96 Million | $137.26 Million | 5.35x | 10.51x |
| 2021 | $1.04 Billion | $229.83 Million | $92.86 Million | 4.52x | 11.20x |
| 2022 | $1.16 Billion | $196.34 Million | $49.36 Million | 5.93x | 23.60x |
| 2023 | $790.52 Million | $158.15 Million | $1.14 Million | 5.00x | 695.26x |
| 2024 | $1.28 Billion | $174.85 Million | $26.12 Million | 7.33x | 49.06x |
Competitor Companies of PHMMF by Market Capitalization
Companies near Pharma Mar SAU in the global market cap rankings as of March 18, 2026.
Key companies related to Pharma Mar SAU by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Pharma Mar SAU Historical Marketcap From 2015 to 2025
Between 2015 and today, Pharma Mar SAU's market cap moved from $891.92 Million to $ 1.51 Billion, with a yearly change of 5.71%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $1.51 Billion | +17.58% |
| 2024 | $1.28 Billion | +62.13% |
| 2023 | $790.52 Million | -32.13% |
| 2022 | $1.16 Billion | +12.00% |
| 2021 | $1.04 Billion | -27.93% |
| 2020 | $1.44 Billion | +85.14% |
| 2019 | $779.45 Million | +226.44% |
| 2018 | $238.77 Million | -59.67% |
| 2017 | $591.98 Million | +4.35% |
| 2016 | $567.32 Million | -36.39% |
| 2015 | $891.92 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Pharma Mar SAU was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.51 Billion USD |
| MoneyControl | $1.51 Billion USD |
| MarketWatch | $1.51 Billion USD |
| marketcap.company | $1.51 Billion USD |
| Reuters | $1.51 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.